Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.54 |
| ▸ | RXRA | P19793 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455594 | 0.91 | NR1H2 (0.56) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL16455597 | 0.88 | NR1H2 (0.50) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL15229733 | 0.86 | RXRA (0.56) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL16455598 | 0.86 | NR1H2 (0.48) | NR1H2NR1H3RXRACARM1CA9 | |
| SCHEMBL16455285 | 0.86 | NR1H2 (0.55) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL16455247 | 0.85 | NR1H2 (0.60) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL16455645 | 0.85 | ALDH1A1 (0.44) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL3471844 | 0.84 | NR1H2 (0.78) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL19633205 | 0.83 | NR1H3 (0.51) | NR1H2NR1H3RXRAALDH1A1MAPT | |
| SCHEMBL16455652 | 0.82 | NR1H2 (0.48) | NR1H2NR1H3RXRAALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-3441390-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | Ralexar Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9637481-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | RALEXAR THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8987318-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | NR1H2 1/4885NR1H3 2/4885RXRA 3/4885 |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | NR1H2 1/4885NR1H3 2/4885RXRA 3/4885 |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRG | NR1H2 1/4885NR1H3 2/4885RXRA 4/4885 |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRA | NR1H2 1/4885NR1H3 2/4885RXRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.